SCHEMBL3390149

SCHEMBL3390149

CC(C)(N)C(C)(Cc1ccccc1)c1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 2/20 0.59
SLC6A2 P23975 1/20 0.59
CYP1A2 P05177 4/20 0.47
CYP2C19 P33261 2/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2D6 P10635 2/20 0.45
LMNA P02545 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
HIF1A Q16665 1/20 0.44
CYP3A4 P08684 2/20 0.44
RECQL P46063 1/20 0.44
MAPK1 P28482 1/20 0.42
KIF11 P52732 2/20 0.42
PRMT1 Q99873 1/20 0.41
KCNN4 O15554 1/20 0.41
MAPT P10636 1/20 0.41
KMT2A Q03164 1/20 0.41
TRPA1 O75762 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3698481 0.83 TAAR1 (0.52) TAAR1SLC6A2CYP1A2CYP2C19CYP2C9
SCHEMBL10435987 0.82 MAPT (0.50) TAAR1SLC6A2CYP1A2CYP2C19CYP2C9
SCHEMBL11417037 0.79 TAAR1 (0.48) TAAR1SLC6A2CYP1A2CYP2C19CYP2C9
SCHEMBL855070 0.78 TAAR1 (0.64) TAAR1SLC6A2CYP1A2CYP2C19CYP2C9
Hydrochloric Acid SCHEMBL7266792 0.77 TAAR1 (0.61) TAAR1SLC6A2CYP1A2CYP2C19CYP2C9
SCHEMBL9055685 0.76 SLC6A2 (0.67) TAAR1SLC6A2CYP1A2CYP2C19CYP2C9
SCHEMBL2573964 0.75 TAAR1 (0.58) TAAR1SLC6A2CYP1A2CYP2C19CYP2C9
SCHEMBL2487465 0.75 TAAR1 (0.73) TAAR1SLC6A2CYP1A2CYP2C19CYP2C9
Phentermine SCHEMBL26615 0.75 SLC6A2 (1.00) TAAR1SLC6A2CYP1A2CYP2C19CYP2C9
SCHEMBL516033 0.75 TAAR1 (0.73) TAAR1SLC6A2CYP1A2CYP2C19CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11065205-B2 Immediate/delayed drug delivery DRUG DELIVERY INTERNATIONAL LIMITED (GB) 2021-07-20 US claimed
US-20190125679-A1 IMMEDIATE/DELAYED DRUG DELIVERY UNIVERSITY OF STRATHCLYDE (GB) 2019-05-02 US claimed
EP-2542228-B1 PULSATILE DRUG RELEASE UNIV STRATHCLYDE (GB) 2017-11-29 EP claimed
EP-2542227-B1 IMMEDIATE/DELAYED DRUG DELIVERY UNIV STRATHCLYDE (GB) 2017-11-22 EP claimed
EP-2542226-B1 DELAYED PROLONGED DRUG DELIVERY UNIV STRATHCLYDE (GB) 2017-11-22 EP claimed
US-9474719-B2 Pulsatile drug release UNIVERSITY OF STRATHCLYDE (GB) 2016-10-25 US claimed
US-9283192-B2 Delayed prolonged drug delivery UNIVERSITY OF STRATHCLYDE (GB) 2016-03-15 US claimed
US-20100144657-A1 PHENYLPIPERIDINE MODULATORS OF mu-OPIOID RECEPTORS AUSPEX PHARMACEUTICALS, INC. (US) 2010-06-10 US claimed
US-20250312396-A1 Control of Cellular Redox Levels MCKENNA ELIZABETH (US) 2025-10-09 US disclosed
US-20250114411-A1 SOLID DOSAGE FORMS CONTAINING BACTERIA AND MICROBIAL EXTRACELLULAR VESICLES EVELO BIOSCIENCES INC (US) 2025-04-10 US disclosed
US-12268718-B2 Control of cellular redox levels LABYRINTH HOLDINGS LLC 2025-04-08 US disclosed
WO-2024197124-A9 ARGININE VASOPRESSIN RECEPTOR (AVPR) ANTAGONISTS AND METHODS OF USING THEREOF UNIVERSITY OF MIAMI (US) 2024-12-19 WO disclosed
EP-4404921-A1 SOLID DOSAGE FORMS CONTAINING BACTERIA AND MICROBIAL EXTRACELLULAR VESICLES Evelo Biosciences, Inc. (US) 2024-07-31 EP disclosed
US-20230355689-A1 SOLID DOSAGE FORMS CONTAINING BACTERIA AND MICROBIAL EXTRACELLULAR VESICLES EVELO BIOSCIENCES, INC. 2023-11-09 US disclosed
EP-2983657-A1 TREATMENT OF GASTROINTESTINAL AND OTHER DISORDERS Numedii, Inc. (US) 2016-02-17 EP disclosed
EP-2699579-B1 PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-10-07 EP disclosed
WO-2014165823-A1 TREATMENT OF GASTROINTESTINAL AND OTHER DISORDERS NUMEDII, INC. (US) 2014-10-09 WO disclosed
US-20120329785-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US disclosed
US-20120329780-A1 Novel kinase inhibitors ORIGENIS GMBH (DE) 2012-12-27 US disclosed
US-20100144657-A1 PHENYLPIPERIDINE MODULATORS OF mu-OPIOID RECEPTORS AUSPEX PHARMACEUTICALS, INC. (US) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144657-A1 PHENYLPIPERIDINE MODULATORS OF mu-OPIOID RECEPTORS OPRM1, OPRK1, OPRD1 TAAR1 97/4885SLC6A2 318/4885CYP1A2 501/4885
US-20120329780-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK TAAR1 1897/4885SLC6A2 2761/4885CYP1A2 3832/4885
US-20120329785-A1 Novel kinase inhibitors LRRK2, MYLK2, MYLK3 TAAR1 2096/4885SLC6A2 1855/4885CYP1A2 4700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.